Silence Therapeutics plc (SLN)
NASDAQ: SLN · Real-Time Price · USD
7.05
-0.66 (-8.51%)
Apr 29, 2026, 12:31 PM EDT - Market open

Silence Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
0.5643.2631.6421.6616.79
Revenue Growth (YoY)
-98.71%36.71%46.12%29.01%124.07%
Cost of Revenue
0.2211.8112.8713.4610.08
Gross Profit
0.3431.4518.788.196.7
Selling, General & Admin
45.0852.3926.2225.6827.05
Research & Development
136.74134.7756.9443.5541.59
Other Operating Expenses
2.68----
Total Operating Expenses
184.5187.1683.1669.2368.64
Operating Income
-91.08-63.32-64.38-61.04-61.94
Interest Income
3.545.05--0.01
Interest Expense
-8.62-0.09---0.07
Other Non-Operating Income (Expense)
2.4818.8611.1111.39-
Total Non-Operating Income (Expense)
-2.6123.8211.1111.39-0.06
Pretax Income
-186.41-101.03-53.27-49.65-62
Provision for Income Taxes
-7.58-11.50.960.69-8.71
Net Income
-88.61-45.31-54.23-50.33-53.28
Net Income to Common
-88.61-45.31-54.23-50.33-53.28
Shares Outstanding (Basic)
4746373230
Shares Outstanding (Diluted)
4746373230
Shares Change (YoY)
2.12%24.69%15.21%8.58%8.78%
EPS (Basic)
-1.89-0.99-1.47-1.56-1.80
EPS (Diluted)
-1.89-0.99-1.47-1.56-1.80
Shares Outstanding
47.2347.2239.6235.9429.93
Free Cash Flow
-62.33-67.85-49.52-57.227.43
Free Cash Flow Per Share
-1.32-1.47-1.33-1.780.25
Gross Margin
61.54%72.70%59.34%37.83%39.94%
Operating Margin
-16292.80%-146.38%-203.47%-281.88%-369.02%
Profit Margin
-16139.90%-102.23%-171.37%-232.44%-317.44%
FCF Margin
-11149.60%-156.85%-156.49%-264.22%44.26%
EBITDA
-89.96-62.14-63.76-60.44-61.36
EBITDA Margin
-16092.50%-143.66%-201.50%-279.12%-365.58%
EBIT
-91.08-63.32-64.38-61.04-61.94
EBIT Margin
-16292.80%-146.38%-203.47%-281.88%-369.02%
Effective Tax Rate
4.06%11.38%-1.79%-1.39%14.06%
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q